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Abstract Cardiac arrhythmias are very frequent in fetuses
and newborns. The prognosis depends on the nature of the
arrhythmias but is most often either spontaneously benign or
following short-term medication administration. A correct
diagnosis is essential for both management and prognosis. It
is based on echocardiography during the fetal period and
mainly on history, physical exam, and electrocardiogram after
birth, but other modalities are available to record transient
arrhythmic events. Irregular rhythms are mostly benign and
rarely require therapy. In most fetuses and infants, tachyar-
rhythmias resolve spontaneously or require short-term admin-
istration of antiarrhythmics. Approximately one third of these
may recur later on, especially during adolescence. Persistent
bradyarrhythmias might require pacemaker implantation
when associated with failure to thrive or with risk of sudden
death.Conclusion: Arrhythmias in fetuses and infants are very
common and mostly benign. History, physical exam, and
recording of the arrhythmia are essential to make a correct
diagnosis and establish an appropriate management for the
rare potentially harmful arrhythmias.
Keywords Arrhythmia . Fetus . Newborn . Infant .
Extrasystole . Tachycardia
Abbreviations
ABC Airway, breathing, circulation
AET Atrial ectopic tachycardia
APB Atrial premature beat
AV Atrioventricular
AVB Atrioventricular block
AVNRT Atrioventricular nodal reentrant tachycardia
AVRT Atrioventricular reentrant tachycardia
CHD Congenital heart disease
ECG Electrocardiogram
JPB Junctional premature beat
JET Junctional ectopic tachycardia
PALS Pediatric advanced life support
PJRT Permanent junctional reciprocating tachycardia
SVT Supraventricular tachycardia
VPB Ventricular premature beat
VT Ventricular tachycardia
WPW Wolff-Parkinson-White syndrome
Introduction
Arrhythmias occur as soon as the heart starts to beat and end
on a final irreversible arrhythmia when we die. The same
definition, classification, and therapies apply from fetuses to
adulthood. They are noted in about 2% of the pregnancies and
account for 10 to 20 % of the referrals to fetal cardiology units
[13,20]. The prevalence of arrhythmias in normal infants
(child up to the age of 12 months) is difficult to estimate,
ranging from 0.75 to 14 %, and is higher in children with
congenital heart disease (CHD) [7,32]. Arrhythmia is also a
frequent cause of pediatric cardiology referrals in order to rule
out potentially life-threatening conditions. We review here the
classification, the diagnosis, the management, and the
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outcome of arrhythmias in fetuses and newborns (child under
28 days of age).
Conduction system development
The first heartbeat occurs by 3 weeks post-conception when
the heart is only a primitive tubular structure. Major morpho-
logical remodeling occurs simultaneously with the develop-
ment of the cardiac conduction system, which results by
7 weeks of gestation in a four-chambered heart with synchro-
nous contraction of the atrial and ventricular chambers at a rate
of approximately 110 bpm. Progressively, the sinus node acts
as the primary pacemaker and the heart rate reaches 170 bpm
by 9 to 10 weeks. Later on in gestation, heart rate slowly
decreases. Between 20 and 40 weeks of gestation, the heart
rate is regular, with a range from 110 to 180 bpm and a
maximal beat-to-beat variation of 15 bpm [20,44]. After birth,
heart rate slowly decreases and normal data for all electrocar-
diogram (ECG) time intervals including heart rate and wave
axis have been published (Table 1) [9].
Rhythm analysis
During fetal life, a real-time fetal ECG is not obtainable due to
the parasitic electrical field generated by the maternal heart
and abdominal muscles. Magnetocardiography allows record-
ing of the fetal heart magnetic field instead of the traditional
electric field recorded by ECG. It is actually the best modality
to analyze the fetal heart rhythm [36,48]. However, this tech-
nology is restricted to select centers due to its high cost.
Therefore, the analysis of arrhythmias is routinely based on
the ultrasound assessment of the temporal relationship of atrial
and ventricular contractions. Different ultrasound modalities
(M-mode, Doppler, or tissue Doppler) allow the classification
of the arrhythmias (Fig. 1) [6,13,40]. In some cases, it may
even be superior to ECG for arrhythmia assessment, as atrial
contraction can be identified even when the ventricle is
contracting or during the repolarization phase [37]. A system-
atic analysis of the ultrasound tracing is mandatory. Stepwise
interpretation of the fetal heart rhythm is based on the deter-
mination of rhythm origin, regularity, and relationship be-
tween atrial and ventricular events and rate. Normal fetal
rhythm includes an atrial origin, a regular atrial and ventricular
contraction in a 1:1 fashion, and a normocardic heart rate.
In newborn and infants, analysis of the rhythm relies es-
sentially on the surface ECG. ECG interpretation should fol-
low a similar initial approach with assessment of rhythm
origin, regularity, relationship, and rate (mnemonic: 4R). In
addition, a careful analysis of each wave (P, QRS, and T) and
segment (PR, QT) in each lead will add information on the
type of arrhythmia. For both diagnosis and management, it is Ta
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essential to distinguish a wide or a narrow QRS. Preexcitation
(delta wave) or prolonged QT interval should also be ruled
out.
Irregular rhythm—premature beats
Definition
A premature beat, also called premature contraction, ectopic
beat, or extrasystole can originate from the atria, the atrioven-
tricular junction, or the ventricle, and bypasses the sinus node.
It is by far the most common type of arrhythmia encountered
during the perinatal period, and their incidence in healthy
patients varies greatly depending of the duration of the heart
rhythm assessment from 1 %, when based on a single surface
ECG, up to more than 50 % when based on a 24-h heart rate
monitoring [17,46].
Atrial premature beats (APB)
Incidence
APB account for about 90% of irregular rhythm in fetuses and
infants [17,22].
Diagnosis
On a Doppler or an ECG recording, APB is defined as a
premature beat originating from the atria, which might be
either conducted (generating a ventricular contraction) or
blocked (not conducted through the atrioventricular (AV)
node) (Fig. 2). Prenatally, the demonstration of the atrial origin
of the extra beat is based on the analysis of the timing of the
atrial contraction and the resetting phenomenon of the sinus
node with APB resulting in less than full compensatory pause.
Postnatally, on ECG, P waves resulting from an APB
(called P′) usually have a different morphology than the sinus
P wave. The morphology of the QRS is also helpful since
most of the time a narrow QRS with similar morphology than
sinus QRS is noted following an APB. A P′ wave is some-
times visible in the preceding T wave (Fig. 2).
Management
As arrhythmias can be associated with cardiac malformations
[50], it is important to ensure that a routine mid-trimester fetal
screening scan for cardiac anomalies is performed. If the
APBs are very frequent (more than 5 per minute), persisting
for more than 3 weeks or associated with signs of cardiac
failure or extracardiac anomalies, it is recommended to per-
form a detailed fetal cardiac ultrasound [13]. A weekly mon-
itoring of the fetal heart rate is recommended as long as the
arrhythmia persists to detect the onset of supraventricular
tachycardia (SVT). Indeed, the susceptibility to cardiac failure
in fetuses with SVT and the inability to observe clinical
manifestations justify this strategy. After birth, if the medical
history and the physical exam are free of any cardiac sign or
symptom and the ECG is normal for age except for the
premature beat, monitoring or further investigation are not
recommended. Exceptions are frequent APB and APB arising
from multiple foci seen as P waves with different morphol-
ogies on surface ECG [52].
Fig. 1 Left, Two-dimensional ultrasound image showing the anatomical
proximity of the SVC and the AA. The sample gate can easily be placed
so as to record both proximal parts of SVC and AA. Right, Fetal virtual
ECG (upper panel) and SVC/AADoppler recording (lower panel, Dopp-
ler tracing turned upside down in order to illustrate analogies with the
ECG tracing) in normal sinus rhythm. Ventricular ejection (V) in the AA
appears above baseline. Venous flow is typical with systolic (S) and
diastolic (E) waves below baseline and the retrograde flow wave (A)
due to the atrial contraction above. A late diastolic wave due to atrial
contraction, AA ascending aorta, AV atrioventricular interval, D early
diastolic wave, ECG electrocardiogram, P P wave, R R wave, S systolic
wave, SVC superior vena cava, V ventricular ejection
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Outcome
APBs are mostly benign and remain self-limited with a spon-
taneous resolution after the diagnosis of the arrhythmia before
birth in 95 % of fetuses and by 1 year of age in 95 % of
children [46]. No association with sudden infant death or any
other serious clinical problems has ever been described. The
immaturity of conduction pathways in fetuses is characterized
by an increased number of accessory pathways connecting the
atrial and ventricular myocardium and a high rate of APB
[31]. Both phenomena are responsible for the peak incidence
of SVT by an atrioventricular (AV) reentrant mechanism
during fetal life, which occurs in approximately 1 to 3 % of
fetuses with APB [13,20]. After birth, with the maturation of
the conduction pathways, both APBs and SVTs tend to be
self-limited [45]. Occasionally, APB can be associated with
cardiac malformations, such as atrial septal defect. In sick
babies, other causes should be ruled out: mechanical problems
(central venous line, atrial distension), metabolic anomalies
(hypo- or hyperkaliemia, hypercalcemia, hypoglycemia,
hypoxia), pharmacological causes (antiarrhythmics,
inotropes), or previous cardiac surgery (atrial scar).
Ventricular premature beats (VPB)
Incidence
VPB in fetuses are rare and represent less than 2 % of fetal
premature beats. After birth, the incidence of VPB in infants is
highest in the neonatal period and decreases rapidly thereafter
(incidence of VPBs on 24 h ambulatory ECG decreasing from
18 to 6 %, respectively) [17]. Therefore, some authors con-
sider neonatal isolated monomorphic VPB a variation of
normal rhythm [53].
Diagnosis
AVPB is diagnosed when, on a Doppler or an ECG recording,
a premature ventricular beat is observed without any alteration
of the atrial rate, giving rise to a full compensatory pause after
the extra beat (Fig. 3). On ECG, a premature wide QRS,
usually with a different morphology than the preceding
QRS, makes the diagnosis easier postnatally.
Management
Prenatally, a careful exam of the cardiac anatomy and function
should be performed to detect malformation or signs of car-
diac failure. Weekly monitoring of the fetal heart rate is
recommended as long as the arrhythmia persists [13,20]. After
birth, besides a cardiovascular-oriented medical history and
physical exam, an ECG should be obtained. But there is no
agreement on the management of VPB diagnosed postnatally.
Proposed managements are as follows: no further investiga-
tion, repetition of ECG at 1- or 2-month intervals, perfor-
mance of a 24-h ambulatory electrocardiography monitoring
to look for higher grade ectopic activity (nonisolated or poly-
morphic premature beats), and referral to a pediatric cardiol-
ogist for a cardiovascular work-up [27,52]. We believe that if
medical history (personal and familial) and physical exam are
free of any cardiovascular symptoms or signs, and if a pedi-
atric cardiologist has ruled out abnormalities suggesting an
Fig. 2 Upper panel, ECG
showing one nonconducted
premature atrial beat (black
arrowheads) occurring during T
wave after every conducted atrial
beat called bigeminy. This results
in a ventricular bradycardia with a
ventricular rate of 70 bpm. Lower
panel, SVC/AA Doppler
recording showing the same
phenomenon than on the upper
panel with an APB (white
arrowheads) occurring at the end
of the ventricular contraction
which did not result in a
ventricular contraction. A atrial
contraction, AA ascending aorta,
P P wave, R R wave, SVC
superior vena cava, V ventricular
contraction
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underlying myocardial disease on ECG, it is reasonable to
repeat the ECG beyond the neonatal period and perform a
cardiovascular work-up for those who show persistent irregu-
lar rhythm at auscultation or ECG.
Outcome
The prognosis of VPB is also benign in most cases.
However, it may be a manifestation of a serious under-
lying myocardial disease such as cardiac malformations,
tumors, or cardiomyopathies. In most instances, those
could be ruled out by medical history, physical exami-
nation, and ECG.
Junctional premature beats (JPB)
JPB describe premature beats originating from the AV node
area. They are rarely described in fetuses and infants. The
prenatal diagnosis is challenging because differentiation from
VPB might be impossible. On ECG, an early narrow QRS not
preceded by any P wave is diagnostic. Prognosis and man-
agement are similar to those with APBs [52].
Tachycardia
Definition
Tachycardia is defined as an area of the heart that depolarizes
faster than the normal range for age for at least three consec-
utive beats, above 180 bpm in the fetus between 20 and
40 weeks of gestation and above 200 bpm in infants. As for
extrasystoles, supraventricular origin is by far the most fre-
quent cause, with AV nodal and ventricular origins being
infrequent in healthy fetuses and infants. In fetuses, 70 % of
the tachyarrhythmias are paroxysmal AV reentry tachycardia,
24 % primary atrial tachycardias (mostly atrial flutter), and
6 % sinus tachycardia [22]. During infancy, 80 % of nonsinus
tachycardia are AV reentry tachycardia, 15 % are primary
atrial tachycardia (mostly atrial flutter), and 5 % are AV nodal
reentry SVT [32]. The electrophysiological mechanism of all
SVT is described in Table 2. During the perinatal period and
infancy, a reentrant circuit is by far the most common mech-
anism. The reentrant circuit is either involving both the atria
and ventricles, with the abnormal pathway crossing the AV
groove in AV reentry tachycardia and within or just next to the
AV node in AV nodal reentry tachycardia, or limited to the
atria in atrial flutter (AF).
Fig. 3 Upper panel, surface ECG: VPB is diagnosed when a wide
premature QRS complex (black arrowhead) is observed on surface
ECG. Since in rare instances a wide QRS could result from an APB,
another feature of VPB is that the interval between the preceding and the
following sinus beat is equal to twice the time between two regular sinus
beats. This phenomenon called “full compensatory pause” is due, in
contrast to APB, to the absence of resetting of the sinus node in VPB.
Lower panel, SVC/AA Doppler recording: prenatally, since ECG is not
obtainable, this phenomenon is essential to the diagnosis. RR′ interval
before the VPB (white arrowhead) is 515 ms. The interval from the
preceding and the following regular ventricular beat equals 1,017 ms,
approximately twice the RR′ interval (=1,030 ms). Another feature is the
identification of regular atrial contractions (white stars), independent of
the premature ventricular contraction. AA ascending aorta, P P wave, R R
wave, SVC superior vena cava, V ventricular contraction
Eur J Pediatr (2014) 173:983–996 987
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For the purpose of clarity, we will use a common terminol-
ogy based on the depolarized cardiac chamber to characterize
SVTon Doppler recordings and ECG. This means that instead
of the traditional P, QRS waves, and PR interval, we will use
the terms A (corresponding to atrial activity or event), V
(corresponding to ventricular activity or event), and AV inter-
val [52]. This allows to differentiate tachycardias based on the
ratio of atrial versus ventricular events: =1, >1, or <1 and on
the time interval between those events: VA interval < AV
interval, called short VA SVT; or VA interval > AV interval,
called long VA SVT (Table 2; Fig. 4).
Supraventricular tachycardia
Incidence
The incidence of fetal SVT is about 1:3.700 pregnancies [50].
It accounts for about 5 to 10 % of all fetal arrhythmias, but for
more than 50 % of the clinically significant ones [22]. Post-
natally, the incidence ranges between 1:250 and 1:1,000 chil-
dren, with a peak incidence in the neonatal period [17].
Diagnosis
The determination of the type of SVT is based on the assess-
ment of the AV relationship and other specific characteristics
(see Table 2 and Figs 4 and 5). Based on that, sinus tachycar-
dia and ventricular tachycardia should be ruled out since their
management and prognosis differ considerably from nonsinus
SVT. Provoking factors for nonsinus SVT in the fetus have to
be looked for: co-existing CHD, hyperthyroidism, or maternal
caffeine, alcohol, or nicotine consumption. These last causes
are among the most frequent ones [49]. Sinus tachycardia is
the most common cause of long VA tachycardia and the heart
rate is usually lower than in other SVT with frequent gradual
acceleration and slowing. Atrial contractions remain always
clearly visible on Doppler recording prenatally, but on ECG, P
waves might be transiently hidden in the T waves and visible
only when the heart rate decelerates. Maternal fever, drug use,
or hyperthyroidism and hypoxemia are the most frequent
cause in fetuses. During infancy, the same etiologies are
encountered, but hypovolemia due to dehydration or shock
is the leading cause [18].
Management
Acute therapy Classification of SVT is the main step to es-
tablish a prognosis and guide the therapy. Prenatally, due to
the risk of a rapid progression to cardiac failure and the
difficulty to convert SVT in a hydropic fetus, all in utero
sustained SVT should be treated when delivery is not an
option [13,20]. Antiarrhythmic drugs have been used for years
now and adverse events for the mother and the fetus remain
rare. However, any drug administration to a healthy individu-
al, the mother, is a great concern and careful introduction and
monitoring is mandatory. The choice of the drug will depend
mostly on the state of the fetus (signs of heart failure, fetal
hydrops) as well as on the type of SVT. Since no large
prospective randomized controlled trial (RCT) has been un-
dertaken, there is to date no agreement on the best antiarrhyth-
mic. This should be solved in the near future with the
multicentric international RCT planned by Jaeggi et al. Be-
cause of their efficacy and safety, digoxin, sotalol, and
flecainide are the first-line agents most commonly used
(Table 2). All allow monitoring of the dosage based on
their maternal serum level (serum level of sotalol and
Fig. 4 SVT classification. After birth, QRS wideness allows to differen-
tiate SVT from VT. The positive predictive value of a wide QRS for the
diagnosis of VT is very high. Rare false positive cases are due to SVT
with a bundle branch block or with antegrade conduction through an
accessory pathway. Prenatally, without the availability of an ECG, tachy-
cardia could still be differentiated based on the A:V ratio and the AV
interval, except for differentiating JET from VT, both rare entities in
healthy fetuses and newborn. AET atrial ectopic tachycardia, AF atrial
flutter, A Fib atrial fibrillation, AVRT atrioventricular reentrant tachycar-
dia, AVNRT atrioventricular nodal reentrant tachycardia, JET junctional
ectopic tachycardia, PJRT permanent junctional reciprocating tachycar-
dia, Sinus sinus tachycardia, VT ventricular tachycardia
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flecainide might not be available in some centers) and
the corrected QT measurement on maternal ECG. Com-
bination of antiarrhythmics or second-line antiarrhyth-
mics (propafenone, amiodarone) might be used in
hydropic fetuses (Table 2). Indeed, in this situation,
the conversion rate decreases to less than 25 % with
digoxin alone and usually a median of 2 medications
are needed to convert to sinus rhythm [20]. Currently,
the combinations of flecainide + digoxin and sotalol +
digoxin are most commonly used. In severe cases, when
all transplacental therapies have failed, direct adminis-
tration of antiarrhythmic agents either through fetal in-
tramuscular or transumbilical intravenous administration
may be attempted.
The acute management of SVT in infants is based on
pediatric advanced life support (PALS) guidelines from the
American Heart Association [29]. Probable SVT with pulses
and poor perfusion should bemanaged as follows: ABC status
(i.e., airways, breathing, and circulation), oxygen delivery,
cardiac monitoring, and IVaccess. If ECG recording confirms
SVT and the patient is unstable, electrical synchronized direct
current cardioversion 0.5 to 1 J/kg has to be performed im-
mediately. If the patient is hemodynamically stable, vagal
maneuvers trial can be performed as long as adenosine ad-
ministration is not delayed. Vagal maneuvers include diving
reflex and ice bag placement on the face of infants. A mix of
crushed ice with water in a plastic bag or glove should be
applied on the infant face for 10 to 15 s, without compromis-
ing his breathing. In a stable patient, this might be repeated
once. Carotid sinus massage and ocular pressure are not
recommended due to prolonged asystole and potential retinal
detachment, respectively. If not successful, adenosine should
be given at a starting dose of 0.1 mg/kg (maximum 6 mg)
intravenously by rapid bolus followed by saline flush admin-
istered as close to the patient as possible in the largest intra-
venous access. Conversion to sinus rhythm with the starting
dose is frequently not obtained, especially in infants with less
than 25 % conversion with 0.1 mg/kg [11]. Therefore, the
dose should progressively be increased up to 0.3 mg/kg (max-
imum 12 mg) [39]. Administration through umbilical artery
catheter is the only contraindicated route due to the rapid
metabolization of adenosine prior to its reaching the myocar-
dium [30]. Adenosine acts by blocking the AV node and,
therefore, only terminates arrhythmias involving the AV node
such as AV reentrant tachycardia (AVRT) or AV nodal reen-
trant tachycardia (AVNRT). It will not terminate primary atrial
tachycardias such as AF, but it will slow AV conduction and
often unmask the underlying arrhythmia. It is therefore essen-
tial to record the ECG tracing during its administration. Aden-
osine is very effective for terminating SVTand also safe due to
Fig. 5 Typical SVTwith a short VA interval. On the surface ECG (upper
panel), a narrow QRS tachycardia is observed. If we look carefully at the
T wave, a little deflation (black arrowhead) can be observed sometimes
corresponding to the retrograde depolarization of the atria. Prenatally
(lower panel), a tachycardia is also noted on the Doppler recording based
on the ventricular rate, but the atrial contractions are very clearly identi-
fiable following shortly every ventricular depolarization. This phenome-
non called canon Awave is due to the occurrence of the atrial contraction
before the opening of the tricuspid valve (the ventricle is still contracting
and ejecting blood). The VA interval is much smaller than the AVinterval,
83 and 171 ms, respectively, for a heart rate of 240 bpm. A late diastolic
wave due to atrial contraction, AA ascending aorta, AV atrioventricular
interval,D early diastolic wave, R R wave, S systolic wave, SVC superior
vena cava, V ventricular ejection, VA ventriculoatrial interval
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its short half life (less than 10 s). Major side effects are
infrequent, and they include severe bradycardia, asystole,
atrial fibrillation, AV blocks, ventricular arrhythmias, and
bronchospasm. Therefore, during its administration, a resus-
citation cart has to be available at the bedside. In cases when
adenosine is not recommended or unsuccessful, a pediatric
cardiologist should be consulted for further management,
either electrical cardioversion, overdrive pacing via esopha-
geal leads or antiarrhythmic drugs administration. Acute heart
failure is sometimes encountered in long-lasting tachycardia.
In this situation, rapid restoration of sinus rhythm is crucial
and vagal maneuvers and negative inotropes should be
avoided. In this setting, digoxin is a valuable option for acute
and long-term therapy.
AF is managed prior to birth by transplacental antiarrhyth-
mic administration (Table 2, Fig. 4). Conversion to sinus
rhythm is very effective with the administration of sotalol
[34]. Postnatally, electrical cardioversion is the first-choice
therapy either by atrial overdrive pacing or synchronized
direct current cardioversion [3].
Long-term therapy Duration of therapy depends widely on
the type of tachycardia and the difficulties encountered to
convert it. Very little data exists on the postnatal management
for fetuses diagnosed with SVT. Two strategies are mainly
used either to discontinue all therapies at birth, or to continue
antiarrhythmics prophylactically for 6 to 12 months. The first
option is favored for short VA SVT easily converted with a
single drug due to low recurrence rate and the second one for
all other cases (long VA SVT, short VA SVT requiring more
than one antiarrhythmic) [24]. Due to a very low recurrence
rate after successful atrial flutter conversion, a chronic antiar-
rhythmic treatment is recommended neither in fetuses nor in
infants [24,34]. However, it is important to teach parents the
signs that might reflect a recurrent SVT: irritability, poor
feeding, pallor, diaphoresis, and tachypnea. Since those signs
might be subtle and also because of parental anxiety, some
propose to teach parents to check the heart rate of their infant
during sleep or feeding by either placing their hand on the
child’s chest or by using a stethoscope [28].
Postnatally, if a short VA SVT recurred or is newly diag-
nosed, a chronic therapy is usually initiated in infants to
prevent further episodes. Drugs most used are digoxin and
propranolol with similar efficiency [45]. However, since di-
goxin accelerates conduction through accessory pathways
(AP), it is nowadays mostly avoided in children with WPW
syndrome due to the risk of ventricular fibrillation in case of
atrial fibrillation [16,32]. Other antiarrhythmics frequently
used are sotalol, flecainide, propafenone, and amiodarone.
Long-term therapy is usually discontinued after 6 to
12 months. In case of recurrency of SVT after discontinuation
of medical therapy, the antiarrhythmic therapy is maintained
for a longer period.
Other rare forms of SVT, like atrial ectopic tachycar-
dia (AET), permanent junctional reciprocating tachycar-
dia (PJRT), and junctional ectopic tachycardia (JET), are
often more difficult to treat medically than short VA
SVT. They respond poorly to acute management with
adenosine administration, atrial overdrive pacing, or di-
rect current cardioversion. They often require multiple
therapies directed at controlling at least the rate of the
tachycardia when converting to sinus rhythm is not
achievable.
Until recently, radiofrequency ablation in children
less than 5 years of age and weighing less than 15 kg
was restricted to malignant or poorly tolerated arrhyth-
mias [16]. With improving technologies and expertise, it
is now a safe and effective alternative in infants [5].
Catheter ablation should be considered at any age for
SVT associated with aborted sudden death ,arrhythmia-
related syncopal episodes, ,ventricular dysfunction, re-
fractoriness to multidrug therapy, or severe drug-related
side effects [3,5]. This procedure should be performed
only in experienced hands.
Outcome
Studies show that the recurrence rate of paroxysmal SVT is
the lowest for prenatal cases and then inversely related to age
at initial diagnosis [41]. Patients with initial SVT during
infancy have a freedom from SVT at 1 year of age of 90 %,
but approximately one third of them may have recurrences
later in childhood. The reason for the low recurrence rate in
prenatal cases lies probably with two phenomena: the pro-
gressive disappearance of the muscular accessory pathways
connecting the atria and ventricles as the infant’s heart grows
and the low rate of premature beats as initiating events during
infancy [19].
In the recent era, fetal SVT in hydropic fetuses is still
associated with a significant mortality (as high as 17 %) and
morbidity rate (neurological abnormalities reported in 10 to
20 % of cases even after successful treatment) [23,38].
Ventricular tachycardia
Incidence
VT is very rare in fetuses and infants, accounting for less
than 1 % of all tachyarrhythmias and with an incidence
of 0.3 episodes/100,000 infants [16,42]. An underlying
structural heart disease (hypertrophic cardiomyopathy,
long QT syndrome, right ventricular dysplasia, left ven-
tricle noncompaction, congenital cardiac malformation) is
present in approximately half of the pediatric cases.
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Diagnosis
Prenatally, the diagnosis is challenging, but should be
suspected if AV dissociation is observed with more ventricular
contractions than atrial ones on fetal echo. After birth, the
diagnosis is made if, on ECG, there are more than three
consecutive wide QRS beats of ventricular origin occurring
at a faster rate than the underlying rhythm. A rare benign cause
of broad QRS tachycardia in neonates is accelerated
idioventricular rhythm, characterized by a broad QRS on
ECG with a frequency rate slightly higher than the prevailing
sinus rhythm in a perfectly asymptomatic patient. Spontane-
ous conversion to sinus rhythmmight be observed when heart
rate rises due to the infant agitation. Etiology is unknown, and
it is always self-limited, benign, and never evolves toward a
VT [14,42].
Management
Prenatal treatment includes beta-blockers, flecainide, sotalol,
lidocaine, and amiodarone, but due to the very limited number
of cases, success rate of treatment is not clearly established
and a first-line agent remains to be established. Amiodarone
and sotalol have proven to be successful, but there are con-
cerns about their proarrhythmic side effects in case of associ-
ated LQTS. Therefore, some advocate the use of flecainide or
propranolol, which decreases the QT interval and thus the risk
of inducing torsades de pointes. Postnatally, management of
sustained VT also follows the American Heart Association
PALS guidelines: ABC status, oxygen delivery, cardiac mon-
itoring, and IV access and ECG recording for rhythm assess-
ment and electrical synchronized cardioversion 0.5 to 1 J/kg.
Hemodynamically stable infants with VT might be managed
by drug administration with lidocaine or amiodarone [10,33].
In the setting of prolonged QT and torsades de pointes (poly-
morphic ventricular tachycardia), intravenous magnesium sul-
fate is the treatment of choice. The long-term management
still has to be established since, without the occurrence of life-
threatening events or death, VT resolution occurs with and
without outpatient antiarrhythmic medication [33].
Outcome
The outcome of VT depends on its etiology. Congenital heart
disease, cardiomyopathies (hypertrophic, arrhythmogenic
right ventricular cardiomyopathy), long QT syndrome, and
cardiac tumors are associated with a poor outcome.
The mortality reported is 36 % in this population [42].
Inversely, in half of fetuses and infants, VT is observed
in apparently healthy individuals and is associated with
a good prognosis [10,33,42].
Bradycardia
Definition
Bradycardia is defined as an area of the heart that depolarizes
slower than the normal range for age for at least three succes-
sive beats. A ventricular rate in fetuses and infants below
110 bpm and below 100 bpm, respectively, is usually consid-
ered bradycardia [9,13].
Incidence
Bradycardia represents less than 5 % of arrhythmia referral in
fetuses and infants [13].
Etiology
The most common cause is sinus bradycardia. Transient sinus
bradycardia is often secondary to vagal stimulation, frequently
occurring during fetal scan as a result of the pressure applied
to the maternal abdomen and is also noted during deep sleep,
vomiting, and defecation in infants [47]. Persistent sinus bra-
dycardia is often related to cardiac failure and hydrops in
fetuses, but might also be caused by either maternal hypother-
mia or long QT syndrome. In infants, sustained sinus brady-
cardia is mostly related to secondary sinus node dysfunction
(Table 3). Nonsinus bradycardia consists of sinus node dys-
function either idiopathic or related to a CHD pre- or post-
repair, blocked atrial bigeminy (Fig. 2), 2:1 second-degree
atrioventricular block (AVB), or complete AVB. Atrioventric-
ular blocks will be discussed separately in the next section.
Diagnosis
In utero atrial and ventricular contraction rate and relationship
allows identification of the type of bradycardia, either sinus
bradycardia, blocked atrial bigeminy, 2:1 AVB or complete
AVB (Fig. 2). Postnatally, the diagnosis is easily made on
surface ECG.
Management
For all bradycardias, management depends on etiology and
severity, but a close follow-up is always necessary in order to
detect the occurrence of cardiac failure.
Outcome
Usually, blocked atrial bigeminy is not associated with the
development of cardiac failure and converts spontaneously to
sinus rhythm. The outcome of sinus bradycardia depends
highly on the underlying cause.
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Atrioventricular conduction disorders
Complete AV block
Definition
Complete AVB is the complete dissociation between atrial and
ventricular contractions. Atrial and ventricular impulses are
generated independently from each other. Complete AVB
occurring prenatally are equally related to either CHD (left
isomerism, atrioventricular septal defect, corrected transposi-
tion of the great arteries) or maternal autoantibodies (associ-
ated with autoimmune diseases such as systemic lupus ery-
thematosus) [35,47]. Postnatally, the majority is acquired after
surgery for CHD, but carditis (viral myocarditis and Lyme
diseases carditis essentially) and idiopathic causes might be
encountered [35,52].
Diagnosis
The diagnosis is easily made prenatally and postnatally by
identifying atrial and ventricular events, on Doppler or ECG
recording, occurring independently from each other at their
own pace.
Management
When delivery is not an option, therapeutic choices are limit-
ed. It has been suggested that immune-related second-degree
and complete AVB might benefit from transplacental steroid
administration to prevent AV node and fetal myocardial dam-
age, but this is still controversial [21,26,35,43]. Significant in
utero morbidity and mortality has been reported related main-
ly to cardiac failure and hydrops, which occurs in 9 to 27 % of
the pregnancies with a higher rate in those fetuses with asso-
ciated CHD [25,35]. Since with a heart rate below 55 bpm the
prognosis seems very poor, therapies aiming at increasing
heart rate have been proposed. Transplacental salbutamol
showed some effects in increasing the fetal ventricular rate
and case reports describe the use of in utero pacing, but the
clinical benefit of these therapies remains to be demonstrated
[2,21,26,43].
In contrary to prenatal management, postnatal management
is more clearly established due to the possibility of pacemaker
implantation. Advanced second- or third-degree AVB follow-
ing surgery and persisting more than 7 days requires pace-
maker implantation. Nonsurgical advanced second- or third-
degree AVB might be followed conservatively. Criteria for
pacemaker implantation in those patients include the follow-
ing: failure to thrive, cardiovascular symptoms related to the
bradycardia, low cardiac output, and resting heart rate during
infancy less than 55 bpm [5]. Finally, any infant with symp-
tomatic sinus bradycardia or chronotropic incompetence
should be referred for pacemaker implantation [5].
Outcome
Complete AVB with co-existing CHD carries the worst prog-
nosis with only 20–40 % survival beyond the neonatal period
[35]. One-year survival for isolated perinatal complete AVB is
between 80 and 90 %. Dilated cardiomyopathy is observed in
approximately 25 % of the survivors [43,51].
Second-degree AV block
Definition-diagnosis-management-outcome
In second-degree AV block, not every atrial beat is conducted
to the ventricles. The diagnosis is made similarly for all AV
blocks by identifying the atrial and ventricular beats and the
blocked atrial beat, and measuring the AV delay. In Mobitz
type I subtype (Wenckebach), there is a progressive increase
in AV conduction delay ending in a nonconducted atrial beat.
This condition shares the same etiologies and prognosis as
first-degree AVB. It is also a physiologic condition, frequently
observed when vagal tone is more prominent, especially dur-
ing sleep. However, progression to higher degrees of AV
block is possible, especially if it is related to maternal
Table 3 Causes of sinus bradycardia in fetuses or infants
• Primary sinus node dysfunction
– Certain myopathies and inflammatory diseases
– Following cardiac surgery
– Heterotaxy syndrome associated with absent SA node (left isomerism)
• Autonomic mediated
–Hypervagotonia
– Pallid breathholding spells
– Long QT syndrome
• Medication (antiarrhythmics)
• Situational
– Vasovagal syncope
– Carotid sinus pressure
– Eye surgery
• Central nervous system
– Tumors
– Increased intracranial pressure
– Meningitis
• Metabolic
– Hypoxia
– Hypothermia
– Hypothyroidism
– Acidosis
• Sepsis
Adapted from [52]
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autoantibodies exposition. Those have to be searched for
prenatally and appropriate treatment should be established.
An underlying cardiac condition is also possible and has to
be excluded during the prenatal ultrasound and after birth by
history and physical examination. Patient should be referred to
a pediatric cardiologist and a 24-h ambulatory heart rate
monitoring is indicated to observe if the condition is only
transient and related with periods of high vagal tone. If so,
follow-up is not necessary. For the remaining cases, etiologies
should be looked for and a yearly follow-up is suggested.
In Mobitz type II second-degree AV block, there is no
progressive lengthening of the AV conduction, but rather a
sudden interruption of AV conduction. This is a rare but more
serious condition than type I, often related either to inflamma-
tion (maternal autoantibodies) or traumatic injury. There is a
higher risk for progression to complete AVB, especially for
advanced second-degree AV block (defined as the blocking of
two or more consecutive P waves). Therefore, pacemaker
implantation is indicated when such block occurs following
surgery [5]. Its incidental finding in an asymptomatic patient
can bemanaged conservatively, but deserves careful follow-up.
First-degree AV block
Definition-diagnosis-management-outcome
In first-degree AV block, every atrial beat is conducted to the
ventricles with some delay. The diagnosis is based on the
measurement of a prolonged AV or PR interval for age on
Doppler recording or ECG. AV interval increases slightly
through gestation and normal data varies depending on the
technique used [1,12]. Normal PR interval is less than 160 ms
the first day of life and decreases progressively down to
130 ms at 3 months of age [1,9]. Then its upper limit rises
up to 150 ms and to 160 ms from 3 to 6 and 6 to 12 months,
respectively (Table 1).
First-degree AV block is a benign condition and is well
tolerated. It does not require any therapy, but it might reflect
damage from maternal autoantibodies to the conduction path-
way. This should be looked for prenatally and followed appro-
priately [15]. A careful medical history and physical exam has
to be performed to rule out other underlying cardiac diseases.
This is mostly a benign condition, physiological in most
instances, encountered in infants with high levels of vagal
tone, especially during sleep, but it can also be associated with
CHD, antiarrhythmic medication, hypothyroidism, myocardi-
al inflammation, or surgical trauma [52].
Conclusion
Arrhythmias in fetuses and infants are very common. History,
physical exam, and recording of the arrhythmia are the
cornerstones of the management. Doppler echocardiography
and ECG are the preferred methods for the prenatal and
postnatal periods, respectively. Premature beats are almost
always benign. The most common SVTs, AV re-entrant tachy-
cardia and atrial flutter, carry an excellent prognosis. Acute
and chronic antiarrhythmic medications are available to treat
and prevent recurrent SVT until spontaneous resolution of the
tachyarrhythmia occur, as is the case in up to 90 % of the
treated fetuses and infants. If therapy fails, which is more
common for rarer forms of SVT, electrophysiological study
and catheter ablation could be an option. Due to the increased
risks of such procedures in infants, it has to be undertaken in
experienced hands. Complete AVB is a serious condition with
significant morbidity and mortality, especially when associat-
ed with CHD and may need pacemaker implantation.
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